2. Signaling Pathways
  3. NF-κB
  4. NF-κB
  5. c-Rel Isoform

c-Rel

c-Rel, a member of the NF-κB/Rel transcription factor family, functions as a central regulator of immune cell proliferation, survival, and effector activity, particularly in hematopoietic lineages[1][2]. Mechanistically, c-Rel directly regulates transcription of genes essential for T-cell differentiation, including Il2 and Foxp3, and controls IL-12 and IL-23 production in macrophages and dendritic cells, thereby influencing adaptive immunity[2][3]. Compared with other NF-κB isoforms, c-Rel exhibits tissue-restricted expression, predominantly in lymphoid cells, and demonstrates non-redundant phenotypes in knockout models, indicating unique regulatory functions[1][2]. In disease contexts, aberrant c-Rel activation is implicated in B cell lymphomas, autoimmune disorders, and graft-versus-host disease, with c-Rel deficiency mitigating GVHD while preserving graft-versus-leukemic effects in murine transplantation models[4][5]. Experimental applications leverage c-Rel modulation via genetic knockout or pharmacological inhibition, highlighting its potential as a target for immunomodulation and cancer therapy[2][5][6]. Selective inhibitors, including protein kinase C (PKC) modulators, can suppress c-Rel-dependent transcription without affecting DNA binding, providing isoform-specific intervention opportunities[6]. Overall, the distinct signaling, isoform-specific expression, and disease relevance of c-Rel underpin its value in mechanistic studies and therapeutic design.

c-Rel Related Products (2):

Cat. No. Product Name Effect Purity
  • HY-125864
    Fibrinogen (Bovine)
    		Activator
    Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases.
  • HY-124179
    IT-901
    		Inhibitor 99.32%
    IT-901 is an orally active and potent NF-κB subunit c-Rel inhibitor with an IC50 of 0.1 μM, 3 μM for NF-κB DNA binding and c-Rel DNA binding, respectively. IT-901, a bioactive naphthalenethiobarbiturate derivative, has the potential for human lymphoid tumors and ameliorate graft-versus-host disease (GVHD).